Psoriasis

>

Latest News

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces / image courtesy of Arcutis
Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces

May 8th 2025

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

April Issue of Patient Care Digital Edition is Now Live
April Issue of Patient Care Digital Edition is Now Live

March 27th 2025

Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial
Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial

March 7th 2025

 New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures / image credit ©InfiniteStudio/AdobeStock
New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures

January 20th 2025

© 2025 MJH Life Sciences

All rights reserved.